Wolverine Trading, LLC Lexicon Pharmaceuticals, Inc. Transaction History

Wolverine Trading, LLC

$94.2 Billion
Q2 2024

A detailed history of Wolverine Trading, LLC transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Wolverine Trading, LLC holds 19,000 shares of LXRX stock, worth $29,830. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,000

Previous 21,000 9.52%

Holding current value

$29,830

Previous $50,000 38.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.0 - $1.53 $3,396 - $5,195	-3,396 Reduced 19.5%	14,018 $21,000
Q3 2023 Nov 15, 2023	SELL	$1.06 - $2.33 $3,471 - $7,630	-3,275 Reduced 15.83%	17,414 $18,000
Q2 2023 Aug 23, 2023	BUY	$2.15 - $3.49 $44,481 - $72,204	20,689 New	20,689 $47,000
Q2 2022 Aug 15, 2022	BUY	$1.31 - $2.69 $11,157 - $22,910	8,517 Added 62.39%	22,169 $50,000
Q3 2021 Nov 12, 2021	SELL	$3.38 - $5.35 $84 - $133	-25 Reduced 0.18%	13,652 $67,000
Q2 2021 Aug 06, 2021	BUY	$4.12 - $5.87 $5,079 - $7,237	1,233 Added 9.91%	13,677 $68,000
Q4 2020 Feb 12, 2021	BUY	$1.05 - $3.67 $1,303 - $4,554	1,241 Added 11.08%	12,444 $41,000
Q2 2020 Aug 13, 2020	BUY	$1.75 - $2.3 $19,605 - $25,766	11,203 New	11,203 $22,000
Q1 2020 May 11, 2020	SELL	$1.8 - $4.28 $36,289 - $86,289	-20,161 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$3.16 - $5.15 $47,722 - $77,775	-15,102 Reduced 42.83%	20,161 $83,000
Q3 2019 Nov 14, 2019	SELL	$1.2 - $6.66 $1,222 - $6,786	-1,019 Reduced 2.81%	35,263 $121,000
Q1 2019 May 15, 2019	BUY	$4.36 - $7.94 $158,189 - $288,079	36,282 New	36,282 $202,000

Others Institutions Holding LXRX

# of Institutions

131

Shares Held

240M

Call Options Held

617K

Put Options Held

286K

View Full List

About LEXICON PHARMACEUTICALS, INC.

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $296M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

More about LXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.

Account

Wolverine Trading, LLC Lexicon Pharmaceuticals, Inc. Transaction History